Coronary/Structural Heart

Dr. Stephen J. Hoenig Completes First-of-its-Kind Procedure at The Vascular Care Group, Leominster

Minimally invasive procedure decreases recovery time and demonstrates new opportunities in outpatient care LEOMINSTER, Mass.–(BUSINESS WIRE)–The Vascular Care Group (TVCG), a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, today announced Stephen J. Hoenig M.D. successfully completed a percutaneous femoral-popliteal artery bypass at the Leominster, Mass. […]

Medtronic Announces Approval of the Evolut™ PRO TAVR System in China

First Medtronic TAVR system approved in China for patients with symptomatic severe aortic stenosis DUBLIN, Jan. 10, 2022 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the National Medical Products Administration (NMPA) has approved the CoreValve™ Evolut™ PRO TAVR system for the treatment of severe aortic stenosis (AS) […]

DiNAQOR Announces Research Collaboration with Children’s Medical Research Institute to Develop Novel, Cardiac Specific Capsids

DiNAQOR retains option rights to own the co-developed capsids for the fields of cardiovascular and kidney disease ZURICH-SCHLIEREN, Switzerland and WESTMEAD, NSW, Australia, Jan. 10, 2022 /PRNewswire/ — DiNAQOR, a genetic medicine platform company focused on addressing severe inherited cardiac diseases, today announced it has entered into a research collaboration with Children’s Medical Research Institute (CMRI) in Australia to develop […]

LianBio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

EXPLORER-CN trial designed to support regulatory filing in Mainland China SHANGHAI, China and PRINCETON, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in […]

Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs

VERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022 ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022 Preclinical Data in Non-Human Primates Demonstrate Potential to Re-Dose or Sequentially Dose Base Editing Programs CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, […]

Agilent Presents Thought Leader Award to Professor Jason Kovacic

Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced that Professor Jason Kovacic has been selected to receive a prestigious Agilent Thought Leader Award. Professor Kovacic is being recognized for his influential research on cardiovascular disease—specifically the […]

Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study

DANVERS, Mass.–(BUSINESS WIRE)–Regulators in three countries have granted approvals to Impella surgical products, as Abiomed (NASDAQ: ABMD) continues to execute its strategy for sustainable growth with new products, new indications and new geographies. In the United States, the Food and Drug Administration (FDA) has granted an Early Feasibility Study (EFS) Investigational Device […]

Medtronic to Acquire Affera

Acquisition to expand company’s cardiac ablation portfolio, including first-time entry into mapping and navigation, within one of the fastest growing medtech markets DUBLIN, Jan. 10, 2022 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has entered into a definitive agreement to acquire Affera, Inc., […]

Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States

Evkeeza is a first-in-class medicine approved by the U.S. Food and Drug Administration (FDA) and European Commission (EC) to treat an ultra-rare inherited form of high cholesterol TARRYTOWN, N.Y. and NOVATO, Calif., Jan. 7, 2022 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Ultragenyx Pharmaceutical Inc. today announced a license and collaboration agreement for Ultragenyx to […]

Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million

Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif. and NEW YORK, Jan. […]